Market Insight: By: Echoe Bouta, PhD, Scott Terchiak, and Oded Ben-Joseph, PhD, MBA
The ophthalmology market values innovative approaches, demonstrated by premiums paid for acquisition of first-in-class therapies and public market support of ophthalmology gene therapy companies.
Total economic burden of vision loss and eye disorders surpasses $130 billion in the U.S., a figure expected to rise due to the aging population. We examined recent ophthalmology market dynamics between 2015 and 2018, including industry-sponsored clinical trials, financing events, mergers and acquisition transactions and initial public offerings. These dynamics are utilized to assess the overall activity of the sector and interest by venture capitalists, strategic players and the public market.
Tuesday, July 23 6:00-7:30pm Cost: This event is hosted by Dr. Oded Ben-Joseph (Darwin 1988), Managing Director, Outcome Capital, LLC, and is free to attend with prior RSVP. Outcome Capital, LLC 99 High Street, Suite 2900 Boston, MA RSVP to Megan Cokely at firstname.lastname@example.org Cambridge in America’s Boston Regional Committee invites you to another exclusive event for […]Read More
Outcome Capital Secures Growth Capital for Whisker Labs November 26, 2019, Reston, VA Outcome Capital, an investment banking firm that serves middle market growth companies in the technology and life sciences space, is pleased to announce that Whisker Labs, Inc. (the “Company”) has secured growth capital from State Farm Ventures and Ferguson Ventures along with […]Read More